best fiber while on glp 1 Optimal GLP-1 – Optimal Health Systems Supergut GLP Fiber's Fit for GLP-1 Consumers

%Daily Value

Metabolic Syndrome Resolution Post-hoc analysis of SURPASS trials demonstrated substantial reductions in metabolic syndrome prevalence: Significant improvements in multiple cardiovascular risk factors simultaneously Reductions in blood pressure, improved lipid profiles, and decreased waist circumference Resolution of metabolic syndrome criteria in a substantial proportion of participants Potential long-term cardiovascular benefits from comprehensive metabolic improvements Cardiovascular and Metabolic Comorbidities Heart Failure with Preserved Ejection Fraction (HFpEF) The SUMMIT phase 3 trial evaluated GLP2 in adults with HFpEF and obesity: Statistically significant reduction in heart failure outcomes (composite endpoint) Improvements in heart failure symptoms and physical limitations measured by Kansas City Cardiomyopathy Questionnaire Enhanced exercise capacity as measured by 6-Minute Walk Test Distance Reduction in high-sensitivity C-reactive protein (inflammation marker) These findings established GLP2 as the first incretin therapy to demonstrate benefits on heart failure outcomes in this population

Study selection Firstly, studies were assessed by title verification between databases (duplicates were removed)

Potes, C